In the pivotal Phase 3 ADMIRAL study, AML patients with R/R FLT3‐mutated AML were randomized between 120‐mg/day gilteritinib and a standard of care with high or low intensity regimen defined by physicians prior to randomization [70]. This evidence concerns the gene FLT3 and acute myeloid leukemia.